Announcement to marketing authorisation holders
Under an amendment to the Health Insurance Act that entered into force at the beginning of 2025, the reasonable wholesale prices of nearly all medicines authorised in 2010 and after that were reduced by 1.5 per cent from the beginning of March 2025. For a medicinal product subject to conditional reimbursement, the price reduction will be taken into account in connection with the processing of the reimbursement status and wholesale price application following the entry into force of the Act. The validity of decisions on conditional reimbursement status may be at most five years, which means that the effects of the change will continue for a long time.
At the meeting on 6 March 2025, the Pharmaceuticals Pricing Board discussed how the legislative amendment should be taken into account in non-public contract prices when conditional reimbursement status is to be reformed. The Board considered that contract prices should also be reduced by at least 1.5 per cent when renewing the conditional reimbursement status to remain the same relative difference between the public and the contract price. However, when agreeing on a new contract price, other factors that may affect price formation must also be taken into account as usual.
Inquiries
Reima Palonen, Director, tel +358 295 163 090
E-mail firstname.lastname@gov.fi